EVOTEC

EVOTEC, founded in 1993, is a global, data-driven platform company focused on discovering and developing highly effective therapeutics for patients. Operating within the Business Services sector, EVOTEC utilizes a unique multimodality platform and innovative technologies for both proprietary and partnered research, aiming to deliver first-in-class and best-in-class pharmaceutical products. Its extensive product and service offerings encompass biomarker discovery, drug discovery, protein analysis, and advanced cell and molecule development, positioning it as a significant entity in the life sciences and biotechnology industries. The company's mission is to accelerate therapeutic advancements and make them globally accessible.

With a substantial operational scale, EVOTEC employs between 1,000 and 5,000 individuals across 14 global locations. This infrastructure supports its comprehensive research and development initiatives, including high-throughput screening, chemical development, and manufacturing services that cover the entire drug discovery pipeline from target identification to API production. EVOTEC fosters innovation through collaborative models, partnering with academic institutions, patient advocacy groups, and investors to expedite the translation of scientific discoveries into viable treatments. For insights into the personnel driving these innovations, you can Meet EVOTEC's team.

Financially, EVOTEC reported a revenue of $886.1M. The company has secured substantial funding through various means, including debt financing from the European Investment Bank and private equity rounds involving investors like Mubadala and Novo Holdings, alongside grants from entities such as the Bill & Melinda Gates Foundation. This financial backing fuels its extensive R&D activities and global expansion. EVOTEC is publicly traded under the ticker NASDAQ: EVO, underscoring its established market presence. Detailed financialView more...